Abstract:Bulky non-small cell lung cancer (NSCLC) is difficult to achieve effective local control by conventional radiotherapy (CRT). The present work aims to evaluate the safety and efficacy of partial stereotactic ablative boost radiotherapy (P-SABR) in bulky NSCLC. From Dec 2012 through Aug 2017, 30 patients with bulky NSCLC treated with P-SABR technique were analyzed. The P-SABR plan consisted of one partial SABR plan (5-9 Gy/f, 3-6 fractions) to gross tumor boost (GTVb) followed by one conventional plan to the planning target volume (PTV). GTVb was the max volume receiving SABR to guarantee the PTV margin dose falloff to about 3 Gy/f. And the total dose of PTV margin was planned to about 64Gy. The simply CRT plans were created using the same planning parameters as the original plan, with the goal to achieve comparable organs-at-risks (OARs) doses and PTV margin dose to P-SABR plan. Dosimetric variables were acquired in both P-SABR and compared CRT plans. Toxicity, local control and survival were also evaluated. A total of 27 patients (90%) were male, 3 patients (10%) was female. Median age at treatment was 64.5 years (40 to 85 years). 26 patients were pathologically diagnosed as having NSCLC. 3 patients (10%) had stage IIB(T3N0M0), 9 patients (30%) had stage IIIA, 6 patients (30%) had stage IIIB and 12 patients (40%) had stage IV. Median volume of the tumor treated by P-SABR was 138.07cm3(25.55 to 495.50 cm3) with a median maximal diameter of 8.08cm (4.62 to 14.64 cm). Median follow up-was 9.5 months (range 2.2-39.4 months). No severe acute side effects >CTCAE Grade III were observed. 1-year overall survival was 88.2%. 2-year overall survival was 55.6%. Local response was achieved in 27 of these 30 patients (90%). 11 patients (36.7%) had PR, 10 patients (33.3%) had SD and 9 patients (30%) had PD. 7 patients (23.3%) had local response but systemic progression and 3 patients (10%) presented with a RT-in-field-progression. 1-year local control rate was 100%.2-year local control rate was 85.7%. Patients with B90≥65% achieved higher local control rate than those with B90<65% (p=0.010). P-SABR had significantly higher HI index (p<0.001), while the similar CI index (p>0.5). No differences were found in Dmin and D98 of PTV between P-SABR and the simply CRT plans (p>0.1). Compared to the conventional plan, P-SABR plans increased dose at the isocenter, BED at the isocenter, Dmean and Dmax by 17.89%,26.31%, 7.75% and 14.39%, respectively (p<0.001). We define B80 as the ration of volume of BED>80Gy to the in-field tumor. B80, B90, B100, B110, B120, V65, V70, V75 and V80 were improved by 27.91%, 74.11%, 96.10%, 99.90%, 100.00%, 33.72%, 61.64%, 68.54% and 80.51% in P-SABR plan (p<0.05). P-SABR is feasible and well tolerated in bulky NSCLC. Local control rate is encouraging, especially for B90≥65% group, which may due to the ability of P-SABR to optimize BED with equivalent toxicity.

Stereotactic Ablative Radiotherapy Boost to Bladder Tumor for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer

Combined Modality Therapy Following Bladder Conservation Surgery for Bladder Cancers

Stereotactic Radiotherapy Boost as Part of Tri-Modality Treatment for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer

A Role of Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer Plus Hydronephrosis with or Without Pelvic Nodal Involvement.

Hypo-Fractionated Radiotherapy Boost and Concurrent Chemo-Radiotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): A Preliminary Report of the Prospective Phase II Study

Partial Stereotactic Ablative Radiotherapy in Bulky Urinary Tract Malignancy: an Update Clinical Outcomes and Dosimetric Analysis

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report

Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Stereotactic Ablative Brachytherapy: Recent Advances in Optimization of Radiobiological Cancer Therapy

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer

Transurethral Resection of Bladder Tumor (TURBT) Followed by Partial Hypo-Fractionated Radiotherapy Concurrent with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): Acute Toxicities of a Prospective Phase II Study

Partial Stereotactic Ablative Boost Radiation Therapy in Bulky Bladder/Urothelial Cancer

2375P Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery

Bladder Preservation by Internal Iliac Arterial Infusion Chemotherapy and Radiotherapy in Invasive Bladder Carcinoma

Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients.

Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer